Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study

Date

21 Oct 2023

Session

Poster session 13

Topics

Response Evaluation (RECIST Criteria);  Immunotherapy

Tumour Site

Melanoma

Presenters

Anna Czarnecka

Citation

Annals of Oncology (2023) 34 (suppl_2): S651-S700. 10.1016/S0923-7534(23)01941-5

Authors

P. Teterycz1, K. Ostaszewski1, P. Blonski1, M.K. Zielińska1, L. Galus2, R. Dziura3, N. Kempa-Kamińska4, B. Cybulska-Stopa5, J. Mackiewicz2, M. Ziętek6, P. Rutkowski1

Author affiliations

  • 1 Department Of Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 2 Department Of Medical And Experimental Oncology, Institute Of Oncology, Poznan University of Medical Sciences, 60-780 - Poznan/PL
  • 3 Deparment Of Clinical Oncology, Holy Cross Cancer Center, 25-734 - Kielce/PL
  • 4 Department Of Clinical Oncology, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 - Wrocław/PL
  • 5 Department Of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Kraków/PL
  • 6 Department Of Oncology, Wrocław Medical University, 53-413 - Wroclaw/PL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1176P

Background

The optimal duration of immunotherapy (ITH) for patients(pts) with unresectable/metastatic melanoma has not been defined and de-escalation strategies are under debate. Drug holidays are defined as intentional cessation of immunotherapy for period of time, in pts with therapy benefits, till potential progression (PD). While avails of drug holidays include reduction of toxicity and treatment cost as well as increased quality of pts' life, there are also potential risks including PD. Our study aimed to describe disease control upon drug holidays in melanoma pts treated with palliative ITH.

Methods

Pts with advanced unresectable/metastatic melanoma were treated with anti-PD1-based ITH. Patients were referred for drug holidays after ≥12 months of ITH. Pts who stopped the treatment due to toxicity were excluded from analysis. During study patients had imaging every 3 months. Primary endpoint was overall survival (OS), and secondary endpoints were median duration of drug holiday, 2nd progression-free survival (PFS2) after PD on drug holidays.

Results

175 patients (80F/95M) treated for advanced unresectable/metastatic melanoma were referred for drug holidays. 116(67.4%) were BRAF-negative melanoma patients. 84 pts were treated with nivolumab, 6 with nivolumab+ipilimumab, 85 with pembrolizumab; and 152(86.9%) were treated in first line. Patients treated for ≥24 months(m) before drug holidays had significantly longer OS (p=0.003) and longer PFS till disease PD on drug holidays(p=0.00053) in multivariate analysis. PFS was dependent on best response before drug holidays with the longest in CR group (p=0.011). The median duration of drug holidays was 17 m (IQR: 8-24). At the median follow-up of 48 m (95%CI: 45-51), median OS was not reached, and 5-year OS rate was 89% (95%CI: 83-96). At ITH retreatment objective response was 64% and PFS2 rate at 1-year was 69% (95%CI: 48-99). At the time of analysis 141 pts were still on drug holidays and 11 died due to melanoma PD.

Conclusions

For melanoma pts drug holidays may be offered to ITH responders. The majority of melanoma patients on drug holidays are progression-free at 24m after ITH discontinuation. ITH rechallenge allows achieving disease control after initial progression on drug holidays.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A.M. Czarnecka: Financial Interests, Personal, Invited Speaker: BMS, MSD, Novartis, Pierre Fabre. P. Teterycz: Financial Interests, Personal, Other, travel grant: Sanofi. L. GalusR. Dziura, B. Cybulska-Stopa: Financial Interests, Personal, Speaker’s Bureau: BMS, Roche, MSD, Novartis, Pierre Fabre. J. Mackiewicz: Financial Interests, Personal, Speaker’s Bureau: BMS, GSK, Roche, MSD, Novartis, Pierre Fabre. M. Ziętek: Financial Interests, Personal, Speaker’s Bureau: BMS, MSD, Novartis. P. Rutkowski: Financial Interests, Personal, Invited Speaker, Honoraria for Lectures: MSD, BMS, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, BMS, Pierre Fabre, Merck, Sanofi, Blueprint Medicines, Philogen; Financial Interests, Personal, Invited Speaker: Merck, Sanofi, Novartis, AstraZeneca; Financial Interests, Institutional, Research Grant, research grant for ISS: Pfizer; Financial Interests, Institutional, Funding, research grant for institution: BMS; Non-Financial Interests, Member of Board of Directors: Polish Society of Surgical Oncology; Non-Financial Interests, Member of Board of Directors, President: Polish Oncological Society. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.